Low-dose, short-term ciclosporin (Neoral®) therapy is effective in improving patients' quality of life as assessed by Skindex-16 and GHQ-28 in mild to severe psoriasis patients

Journal of Dermatology

Volumn 38, Issue 5, 2011, Pages 465-472

  Okubo, Yukari ^a   Natsume, Shoko ^a   Usui, Kae ^a   Amaya, Misato ^a   Tsuboi, Ryoji ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

ciclosporin; GHQ 28; psoriasis; quality of life; Skindex 16

Indexed keywords

COLECALCIFEROL; CREATININE; CYCLOSPORIN A; STEROID;

ABDOMINAL PAIN; ADULT; AGED; ANXIETY; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EMOTION; FUNCTIONAL ASSESSMENT; GENERAL HEALTH QUESTIONNAIRE; GENERAL HEALTH QUESTIONNAIRE 28; HUMAN; HYPERTENSION; INSOMNIA; LOW DRUG DOSE; MEAL; MENTAL HEALTH; MOOD CHANGE; NAIL BED; NAUSEA; PATIENT SATISFACTION; PRURITUS; PSORIASIS; PSORIASIS SEVERITY INDEX; QUALITY OF LIFE INDEX; REMISSION; SIDE EFFECT; SKINDEX 16; STRESS; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79955407534     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2010.01041.x     Document Type: Article

References (36)

1. Finlay AY, Kelly SE,. Psoriasis-an index of disability. Clin Exp Dermatol 1987; 12: 8-11.
2. Finlay AY, Khan GK,. Dermatology life quality index (DLQI)-a simple practical measure for routine clinical use. Br J Dermatol 1994; 19: 210-216. (Pubitemid 24194579)
3. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM,. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-407. (Pubitemid 29418506)
4. Krueger GG, Feldman SR, Camisa C, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000; 43: 281-285. (Pubitemid 30626007)
5. Nemoto O, Nakagawa H, Igarashi A, et al. The results of a satisfaction survey concerning treatment for psoriasis patients. Jpn J Dermatol 2003; 113: 2059-2069.
6. Sampogna F, Sera F, Abeni D,. Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster an analysis. J Invest Dermatol 2004; 122: 602-607. (Pubitemid 38471324)
7. Nakagawa H, Igarashi A,. Clinical importance of evaluation of quality of life in patients with psoriasis: treatment from the patients' point of view. Jpn J Dermatol 2005; 115: 863-870.
8. Sampogna F, Chren MM, Melchi CF, Pasguini P, Abeni D,. Age gender, quality of life and psychological distress in patients hospitalized with psoriasis. Br J Dermatol 2006; 154: 325-331. (Pubitemid 43382705)
9. Okubo Y, Arai K, Fujiwara S, Amaya M, Tsuboi R,. Assessment of the quality of life of patients with psoriasis using Skindex-16 and GHQ-28. Jpn J Dermatol 2007; 117: 2495-2505.
10. Callen JP, Krueger GG, Lebwohl M, et al. AAD: AAD consensus statement on psoriasis therapies. J Am Acad Jermatol 2003; 49: 897-899. (Pubitemid 37314880)
11. Griffiths CEM, Dubertret L, Ellis C, et al. Ciclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol 2004; 150: 11-23. (Pubitemid 38903574)
12. Wall A, Poyner T, Menday A,. A comparison of treatment with dithranol and calcopotriol on the clinical severity and quality of life in patients with psoriasis. Br J Dermatol 1998; 139: 1005-1011. (Pubitemid 29010537)
13. Saraceno R, Andreassi L, Ayala F, et al. Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet®) versus calcipotriol (Daivonex®) in the treatment of psoriasis vulgaris. J Dermatolg Treat 2007; 18: 361-365. (Pubitemid 350223199)
14. Korte J, Valk V, Sprangers M, et al. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy. Br J Dermatol 2008; 158: 375-381.
15. Leon A, Nguyen A, Letsinger J, Koo J,. An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis. Expert Opin Pharmacother 2007; 8: 617-632.
16. Kerkhof PCM, Barker J, Griffiths CEM, et al. Psoriasis: consensus on topical therapies. J Eur Acad Dermatol Venereol 2008; 22: 859-870. (Pubitemid 351837121)
17. Ellis CN, Fradin MS, Messana JM, et al. Cyclosporine for plaque-type psoriasis result of a multidose, double-blind trial. N Engl J Med 1991; 324: 277-284.
18. Ho VC, Griffiths CE, Berth-Jones J, et al. Intermittent short course of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol 2001; 44: 643-651. (Pubitemid 32249523)
19. Ho VC,. The use ciclosporin in psoriasis: a clinical review. Br J Dermatol 2004; 150: 1-10. (Pubitemid 38903573)
20. Flyström I, Stenberg B, Svensson A, Bergbrant I-M,. Methotrexate vs.ciclosporin in psoriasis. Br J Dermatol 2008; 158: 116-121.
21. Nakagawa H, Aiba S, Asahina A, et al. A consensus conference report on psoriasis therapy with cyclosporine MEPC. Jpn J Dermatol 2004; 114: 1093-1105.
22. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstand T,. The impact of psoriasis on quality of life. Arch Dermatol 2008; 137: 280-284.
23. Salek MS, Finlay AY, Lewis JJC, Sumner MI,. Quality of life improvement in treatment of psoriasis with intermittent short course cyclosporine(Neoral®). Qual Life Res 2004; 13: 91-95. (Pubitemid 38315224)
24. Touw CR, Hakkaart-Van Roijen L, Verboom P, et al. Quality life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol 2001; 144: 967-972.
25. Berth-Jones J, Henderson CA, Munro CS, et al. Treatment of psoriasis with intermittent short course cyclosporin (Neoral®). A multicentre study. Br J Dermatol 1997; 136: 527-530. (Pubitemid 27160325)
26. Ohtsuki M, Nakagawa H, Sugai J, et al. Long-term continuous versus intermittent cyclosporin. J Dermatol 2003; 30: 290-298. (Pubitemid 36554137)
27. Higaki Y, Kawamoto K, Kamo T, Horikawa N, Kawashima M, Chren MM,. The Japanese version of Skindex-16: A brief quality-of-life measure for patients with skin diseases. J Dermatol 2002; 29: 693-698. (Pubitemid 35416255)
28. Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ,. Skindex, a quality-of-life measure for patients with skin disease: Reliability, validity, and responsiveness. J Invest Dermatol 1996; 107: 707-713. (Pubitemid 26371086)
29. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ,. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997; 133: 1433-1440. (Pubitemid 27490569)
30. Chren MM, Lasek RJ, Sabay AP, Sands LP,. Measurement properties of Skindex-16: a brief quality of life measure for patients with skin disease. J Cutan Med Surg 2001; 5: 105-110. (Pubitemid 32588315)
31. Goldberg DP, Blackwell B,. Psychiatric illness in general practice. A detailed study using a new method of case identification. Br Med J 1970; 2: 439-443.
32. Tarnopolsky A, Hand DJ, Mclean EK, Roberts H, Wigging RD,. Validity and uses of a screening questionnaire (GHQ) in the community. Br J Psychiatry 1979; 134: 508-515. (Pubitemid 9166406)
33. Goldberg DP, Hillier VF,. A scaled version of the General Health Questionnaire. Psychol Med 1979; 9: 139-145. (Pubitemid 9128448)
34. Banks MH,. Validation of the General Health Questionnaire in a young community sample. Psychol Med 1983; 13: 349-353. (Pubitemid 13071398)
35. Finlay AY,. Current severe psoriasis and the Rule of Tens. Br J Dermatol 2005; 152: 861-867. (Pubitemid 40704922)
36. Hashizume H, Ito T, Yagi H, et al. Efficacy and safety of preprandial versus postprandial administration of low-dose cyclosporin microemulsion (Neoral) in patients with psoriasis vulgaris. J Dermatol 2007; 34: 430-434. (Pubitemid 46956586)